Literature DB >> 6614029

Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital.

G S Hoffman, W A Franck, D A Raddatz, L Stallones.   

Abstract

Twenty-seven adult patients with dermatomyositis or polymyositis were retrospectively evaluated over a mean of four and a half years. Eighty-five percent (23) met the suggested criteria of Bohan and Peter (New England Journal of Medicine, 1975) for definite or probable disease, while 15 percent had possible disease. Upper and lower limb girdle strength was given a value (0 to 5) and averaged. Initially, 26 percent were severely weak and 59 percent moderately weak. All patients were treated with steroids. Within three months, 64 percent had little to no weakness and no patients were severely impaired. These proportions remained relatively constant throughout the study. Eight less severely ill patients received alternate-day prednisone. Only two still require treatment; the remainder have been in remission for a mean period of 19 months. Of 19 who received daily prednisone, five also required cytotoxic drugs and 11 still require treatment. A comparison of the results of this study with those of major urban referral centers reveals that the patients in this study constituted a generally less ill population with a better prognosis. Forty-one percent (11) of patients were able to discontinue all forms of therapy and remain in remission. Thirty percent (eight) achieved remission with only alternate-day steroid therapy, an approach that has been discouraged in the past. Two patients (7 percent) had overt malignancies within one year before to three years after diagnosis of myositis. However, in no instance did a search for occult malignancy give positive results. Cancer detection was accomplished by following clues from history and physical examinations. It is questioned whether extensive evaluations for occult malignancies in patients with idiopathic myositis are cost-effective.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6614029     DOI: 10.1016/0002-9343(83)90344-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review.

Authors:  Eleni Tiniakou; Andrew L Mammen
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

2.  Characterization of relapses in adult idiopathic inflammatory myopathies.

Authors:  Sandeep K Agarwal; Paul A Monach; William P Docken; Jonathan S Coblyn
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

3.  Joint involvement in polymyositis/dermatomyositis.

Authors:  G Citera; M A Gõni; J A Maldonado Cocco; E J Scheines
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

4.  Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in asian population.

Authors:  Patompong Ungprasert; Napat Leeaphorn; Nattamol Hosiriluck; Wikrom Chaiwatcharayut; Nischala Ammannagari; Donald A Raddatz
Journal:  ISRN Rheumatol       Date:  2013-02-25

5.  Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: An analysis of 68 cases.

Authors:  K N Ramesha; Abraham Kuruvilla; P S Sarma; V V Radhakrishnan
Journal:  Ann Indian Acad Neurol       Date:  2010-10       Impact factor: 1.383

6.  Biopsy proven polymyositis in Victoria 1982-1987: analysis of prognostic factors.

Authors:  H Lilley; X Dennett; E Byrne
Journal:  J R Soc Med       Date:  1994-06       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.